Columbia researchers have created personalized probiotic bacteria that train the immune system to eliminate cancer cells. In advanced colorectal cancer and melanoma mouse models, this bacterial vaccine shrunk or eradicated tumors, providing a promising new approach to cancer immunotherapy by precisely targeting tumor-specific mutations.